OSA - Obstructive Sleep Apnea

3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sciwind Biosciences
Sciwind BiosciencesChina - Hangzhou
2 programs
2
XW003 injectionPhase 31 trial
XW003 injectionPhase 31 trial
Active Trials
NCT07387094Not Yet RecruitingEst. Dec 2027
NCT07434050Not Yet RecruitingEst. Jun 2028
Apnimed
ApnimedMA - Cambridge
1 program
1
AD109Phase 21 trial
Active Trials
NCT05071612CompletedEst. Aug 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Sciwind BiosciencesXW003 injection
Sciwind BiosciencesXW003 injection
ApnimedAD109

Clinical Trials (3)

A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy

Start: Mar 2026Est. completion: Jun 2028
Phase 3Not Yet Recruiting

A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy

Start: Mar 2026Est. completion: Dec 2027
Phase 3Not Yet Recruiting

Parallel Arm Trial of AD109 and AD504 In Patients With OSA

Start: Nov 2021Est. completion: Aug 2022
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space